VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the appointment of Blaine McKee, Ph.D., Executive Vice President and Chief Business Officer of ImmunoGen, Inc., to the company’s Board of Directors.
“Blaine is an excellent addition to our Board of Directors, bringing with him a 25-year track record of building successful biotech companies,” said Jeff Baxter, VBI’s president and CEO. “His extensive transactional, strategic, and market access expertise will be invaluable, particularly as our Hepatitis B vaccine, Sci-B-Vac, transitions from clinical development to the commercial stage.”Blaine McKee, Ph.D.Dr. McKee brings more than two decades of experience in the pharmaceutical and biotechnology industries to VBI’s Board of Directors. Before joining ImmunoGen in April 2018, he served as Head of Corporate Development at Shire PLC, where he led corporate strategy, M&A, due diligence, commercial assessment, and alliance management efforts. While at Shire, over a four-year tenure, Dr. McKee was responsible for executing multiple M&A, licensing, and divestment transactions, most recently the sale of Shire’s commercial oncology franchise to Servier S.A.S. for ~$2.4 billion. Dr. McKee’s most significant and recent roles prior to joining Shire include Executive Vice President and Chief Business Officer of 480 Biomedical, as well as a 15-year tenure at Genzyme Corporation, which culminated in the role of Senior Vice President of Strategic Development for the Oncology, Transplant, and Multiple Sclerosis divisions.
Dr. McKee currently serves as Director for the New York Pharma Forum. He received a Bachelor of Science in Chemistry from Colorado State University, a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology (MIT), and an MBA in Finance from the MIT Sloan School of Management.
“I am pleased to join VBI’s distinguished Board of Directors,” said Dr. McKee. “With expected clinical milestones across all four lead programs, 2019 is set to be a pivotal year for VBI. The company’s pipeline has incredible potential in both the infectious disease and oncology setting, and I look forward to working with the VBI team to achieve their ambitious goals.”